Accendra Health (ACH) Cash & Equivalents (2009 - 2026)

Accendra Health (ACH) has reported Cash & Equivalents for 18 consecutive years, with $336.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 466.79% year-over-year to $336.9 million; the TTM figure through Mar 2026 stood at $336.9 million (up 466.79% YoY), while the FY2025 annual figure was $282.0 million, up 922.74% from the prior year.
• Cash & Equivalents improved to $336.9 million in Q1 2026 per ACH's latest filing, from $282.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $336.9 million in Q1 2026 and bottomed at $27.6 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $149.2 million across 5 years, with a median of $76.8 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 88.66% — and 2025, when it surged 922.74%.
• Accendra Health's Cash & Equivalents stood at $69.5 million in 2022, then jumped by 249.86% to $243.0 million in 2023, then slumped by 88.66% to $27.6 million in 2024, then soared by 922.74% to $282.0 million in 2025, then increased by 19.47% to $336.9 million in 2026.
• Business Quant data shows ACH's Cash & Equivalents at $336.9 million in Q1 2026, $282.0 million in Q4 2025, and $32.8 million in Q3 2025.